Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. Direct-acting antiviral agents for genotype 1 chronic hepatitis C

Direct-acting antiviral agents for genotype 1 chronic hepatitis C '); } else { document.write(' '); } ACE | Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C Search > > Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C - Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C First published on 1 October 2018 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sofosbuvir 400 mg (...) /velpatasvir 100 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced, or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin-experienced adults. Sofosbuvir

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

2. Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C

Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C '); } else { document.write(' '); } ACE | Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C Search > > Direct-acting antiviral agent for treating genotype 2 to 6 chronic hepatitis C - Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C First published on 2 January 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sofosbuvir 400 mg (...) /velpatasvir 100 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults; and Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

3. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians

World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your password? Enter your email address below and we will send you the reset instructions Email (...) States, the incidence of hepatitis C virus (HCV) infection is 1.2 per 100 000 persons, the prevalence is 2.4 million cases, and annual mortality is more than 15 000 deaths ( , ). Eliminating hepatitis will require diagnosis of 90% of those infected followed by treatment of 80% of those diagnosed ( ). The World Health Organization (WHO) updated its evidence-based guideline on chronic HCV infection in July 2018 ( ) ( ). Although the WHO guideline is primarily targeted toward policymakers in low

2020 American College of Physicians

4. Hepatitis B virus persistence and reactivation. Full Text available with Trip Pro

Hepatitis B virus persistence and reactivation. Hepatitis B virus (HBV) infection causes chronic hepatitis and has long term complications. Individuals ever infected with HBV are at risk of viral reactivation under certain circumstances. This review summarizes studies on HBV persistence and reactivation with a focus on the definitions and mechanisms. Emphasis is placed on the interplay between HBV replication and host immunity as this interplay determines the patterns of persistence following

2020 BMJ

5. Hepatitis C Virus. (Abstract)

Hepatitis C Virus. Hepatitis C virus (HCV) is the most common bloodborne pathogen in the United States, chronically affecting approximately 2.4 million Americans, most of whom are unaware of the infection. Highly effective, well-tolerated therapies are now available with markedly simplified treatment algorithms. Eradication of HCV is a national goal. Increased efforts to extend access to treatment to populations that traditionally are difficult to treat, such as persons who inject drugs

2020 Annals of Internal Medicine

6. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Copyright © ESPGHAN and NASPGHAN (...) . All rights reserved. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Daniel H. Leung, y James E. Squires, z Ravi Jhaveri, § Nanda Kerkar, jj Chuan-Hao Lin, Parvathi Mohan, # Karen F. Murray, Regino P. Gonzalez-Peralta, yy Eve A. Roberts, and zz Shikha S. Sundaram ABSTRACT In 1989, a collaboration between the Centers for Disease Control (CDC) and a California biotechnology company identi?ed the hepatitis C virus (HCV

2020 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

7. Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy

Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01757 Journal of Clinical Oncology - published online before print July 27, 2020 PMID (...) : Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update , MD, MPH 1 x Jessica P. Hwang ; , MD, MPH 2 x Jordan J. Feld ; , MD 3 x Sarah P. Hammond ; , MD, MPH 4 x Su H. Wang ; , MD, MMM 5 x Devena E. Alston-Johnson ; , JD 6 x Donna R. Cryer ; , MD 7 x Dawn L. Hershman ; , MD, MPH 8 x Andrew P. Loehrer ; , MD 9 x Anita L. Sabichi ; , MD, MACP 10 x Banu E. Symington ; , MD, MPH 11 x Norah Terrault ; , MD, MAS 12 x Melisa L. Wong ; , PhD

2020 American Society of Clinical Oncology Guidelines

8. Bulevirtide (Hepcludex) - chronic (long-term) hepatitis delta virus (HDV)

Bulevirtide (Hepcludex) - chronic (long-term) hepatitis delta virus (HDV) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/312782/2020 EMEA/H/C/004854 Hepcludex (bulevirtide (...) ) An overview of Hepcludex and why it is authorised in the EU What is Hepcludex and what is it used for? Hepcludex is an antiviral medicine used to treat chronic (long-term) hepatitis delta virus (HDV) infection in adults with compensated liver disease (when the liver is damaged but is still able to work), when the presence of viral RNA (genetic material) has been confirmed by blood tests. HDV is an 'incomplete' virus, because it cannot replicate in cells without the help of another virus, the hepatitis B

2020 European Medicines Agency - EPARs

9. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Full Text available with Trip Pro

Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement - The Journal of Heart and Lung Transplantation Go search , P418-432, May 01, 2020 Powered By Mendeley Share on Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Saima (...) Jeffrey Teuteberg,MD Maria Crespo,MD Haifa Lyster,PharmD Laura Lourenco,PharmD Sara Machado,MD Michael Shullo,Pharm D Matthew Hartwig,MD Miranda Peraskeva,MD Cameron Wolfe,MD Kiran Khush,MD Michael Ison,MD Shelley Hall,MD Joshua Mooney,MD Steve Ivulich,PharmD Marcelo Cypel,MD Victor Pretorius,MBBS Patricia Uber,PharmD Evan Kransdorf,MD, PhD Adam Cochrane,PharmD, MPH Alan Glanville,MD Jennifer Gray,PharmD Published: March 18, 2020 DOI: The advent of therapies for successful treatment of hepatitis C

2020 International Society for Heart and Lung Transplantation

10. USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty). (Abstract)

USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty). Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323:970-5. 32119076.

2020 Annals of Internal Medicine

11. Hepatitis C Virus Infection in Adolescents and Adults: Screening

Hepatitis C Virus Infection in Adolescents and Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults aged 18 to 79 years The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years. B View the Clinical Summary in What does the USPSTF recommend? For adults aged 18 to 79 years: Grade B Screen adults for hepatitis C virus (HCV) infection. To whom does (...) evidence to determine how often to screen persons at increased risk. What are other relevant USPSTF recommendations? The USPSTF has made recommendations on screening for hepatitis B virus infection in pregnant persons, hepatitis B virus infection in adults, and HIV infection. These recommendations are available at . Where to read the full recommendation statement? Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation

2020 U.S. Preventive Services Task Force

12. Hepatitis E: symptoms, transmission, prevention, treatment

Hepatitis E: symptoms, transmission, prevention, treatment Hepatitis E: symptoms, transmission, prevention, treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis E: symptoms, transmission, prevention, treatment The symptoms, means of transmission, best means of prevention and treatment of hepatitis E. Published 1 June 2014 Last updated 16 July 2019 — From: Documents HTML Details (...) This document explains hepatitis E, describing the: symptoms means of transmission best means of prevention and treatment Published 1 June 2014 Last updated 16 July 2019 16 July 2019 Added provisional data for January to March 2019. 8 March 2019 Updated the number of hepatitis E cases in 2017 and 2018. 7 November 2018 Added provisional data for January to September 2018. 10 August 2018 Added provisional data for January to June 2018. 1 August 2018 Updated 2017 figures. 1 February 2018 Updated number

2020 Public Health England

13. Screening for Hepatitis C Virus Infection

Screening for Hepatitis C Virus Infection Screening for Hepatitis C Virus Infection | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Screening for Hepatitis C Virus Infection Practice Advisory April 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. . The on March 2, 2020. New guidance from both the CDC and the USPSTF represent a change in routine screening (...) for HCV; both organizations now recommend HCV screening for all adults, including pregnant and nonpregnant individuals. The American College of Obstetricians and Gynecologists (ACOG) is actively reviewing the new guidance from the CDC and USPSTF. Updated guidance from ACOG will be posted on ACOG’s website and published in Obstetrics & Gynecology when available. ACOG is also reviewing its current guidance on the screening and management of hepatitis for pregnant individuals in ACOG Practice Bulletin

2020 American College of Obstetricians and Gynecologists

14. AASLD Guidelines for Treatment of Chronic Hepatitis B

AASLD Guidelines for Treatment of Chronic Hepatitis B Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance Norah A. Terrault, 1 Anna S.F. Lok, 2 Brian J. McMahon, 3 Kyong-Mi Chang, 4 Jessica P. Hwang, 5 Maureen M. Jonas, 6 Robert S. Brown Jr., 7 Natalie H. Bzowej, 8 and John B. Wong 9 Purpose and Scope of the Guidance This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic (...) Hepatitis B (1) and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coin- fections, acute

2020 American Association for the Study of Liver Diseases

15. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing

2020 JAMA

16. Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility Full Text available with Trip Pro

Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility Major liver resection is associated with blood loss and transfusion. Observational data suggest that hypovolaemic phlebotomy can reduce these risks. This feasibility RCT compared hypovolaemic phlebotomy with the standard of care, to inform a future multicentre trial.Patients undergoing major liver resections were enrolled between June

2020 EvidenceUpdates

17. Givosiran (Givlaari) - acute hepatic porphyria

Givosiran (Givlaari) - acute hepatic porphyria Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/62114/2020 EMEA/H/C/004775 Givlaari (givosiran) An overview of Givlaari and why (...) it is authorised in the EU What is Givlaari and what is it used for? Givlaari is a medicine for treating acute hepatic porphyria in patients aged 12 years or over. Acute hepatic porphyria is a rare genetic condition in which the liver cannot properly produce a substance called haem. As a result, substances used to make haem build up in the body, causing attacks of severe abdominal pain, vomiting and nervous system disorders. Acute hepatic porphyria is rare, and Givlaari was designated an ‘orphan medicine

2020 European Medicines Agency - EPARs

18. Toolkit to support the generation of robust estimates of hepatitis C prevalence

Toolkit to support the generation of robust estimates of hepatitis C prevalence TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project www.ecdc.europa.euECDC TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Erika Duffell and Andrew Amato-Gauci, and produced (...) : European Centre for Disease Prevention and Control. Technical protocol for hepatitis C prevalence surveys in the general population. Stockholm: ECDC; 2020. Stockholm, February 2020 ISBN 978-92-9498-423-4 doi: 10.2900/30190 Catalogue number TQ-03-19-928-EN-N © European Centre for Disease Prevention and Control, 2019 Cover picture: © Science Photo Reproduction is authorised, provided the source is acknowledged. For any use or reproduction of photos or other material that is not under the EU copyright

2020 European Centre for Disease Prevention and Control - Technical Guidance

19. Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. Full Text available with Trip Pro

Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. To evaluate the effectiveness and cost effectiveness of a complex intervention in primary care that aims to increase uptake of hepatitis C virus (HCV) case finding and treatment.Pragmatic, two armed, practice level, cluster randomised controlled trial and economic evaluation.45 general practices in South West England (22 randomised

2020 BMJ

20. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Full Text available with Trip Pro

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without

2020 EvidenceUpdates